Incretin-Based Therapies for the Treatment of Type 2 Diabetes: Evaluation of the Risks and Benefits
Open accessThe DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index.
Abstract
T ype 2 diabetes is a complex meta-bolic disorder characterized byhyperglycemia arising from a com-bination of insufficient insulin secretion together with resistance to insulin action. The incidence and prevalence of type 2 diabetes are rising steadily, fuelled in part by a concomitant increase in the world-wide rates of obesity. As longitudinal studies of type 2 diabetes provide evi-dence linking improved glycemic control with a reduction in the rates of diabetes-associated complications, there is consid-erable interest in the therapy of type 2 diabetes (Fig. 1), with a focus on the de-velopment and use of new agents that ex-hibit improved efficacy and safety relative
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Additionally, it was implicated that GLP-1 analogue therapy increased the risk of acute pancreatitis, but subsequent studies using larger cohorts did not confirm this finding.8,267”
From A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives (2021) · cites this paper as [267]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Self-citationNathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Self-citationThe biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210
Self-citationBuse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503 · cited 4×
“Moreover, both exenatide and liraglutide reduce blood pressure, body weight, and plasma lipid profiles in subjects with type 2 diabetes (13), raising the hope that longterm treatment with these agents may reduce the incidence of cardiovascular events.”
BackgroundInfluentialSelf-citationLaboratory Support for the Diagnosis and Monitoring of Thyroid Disease
(2003) · Thyroid · doi:10.1089/105072503321086962 · Cited by 1,212
Nathan, D. M., Buse, J. B., Davidson, M. B., Heine, R. J., Holman, R. R., Sherwin, R., & Zinman, B. (2006) · Diabetes Care · doi:10.2337/dc06-9912 · Cited by 1,203
Self-citationDrucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070
Self-citationOral Antihyperglycemic Therapy for Type 2 Diabetes: Scientific Review
Inzucchi, S. E. (2002) · JAMA · doi:10.1001/jama.287.3.360 · Cited by 1,065
Ban, K., Noyan-Ashraf, M. H., Hoefer, J., Bolz, S.-S., Drucker, D. J., & Husain, M. (2008) · Circulation · doi:10.1161/circulationaha.107.739938 · Cited by 1,057 · cited 1×
“Intriguingly, the GLP-1 metabolite, GLP-1 (9–36), also exerts cardioprotective actions in preclinical studies through mechanisms independent of the known GLP-1R (14); hence, ongoing research is directed at understanding the complexity of incretin biology in the cardiovascular system and the potential for incretin-base…”
BackgroundSelf-citationNikolaidis, L. A., Mankad, S., Sokos, G. G., Miske, G., Shah, A., Elahi, D., & Shannon, R. P. (2004) · Circulation · doi:10.1161/01.cir.0000120505.91348.58 · Cited by 901
Research works printed but not linked: 2
- Horner, SEER Cancer Statistics Review, 1975–2006 [Internet], 2009
- Parola, 2009, FDA Advisory Committee Nonclinical Briefing Document, NDA, 22
Cited by
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
Elashoff, M., Matveyenko, A. V., Gier, B., Elashoff, R., & Butler, P. C. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.018 · Cited by 944
Future directions for peptide therapeutics development
Kaspar, A. A., & Reichert, J. M. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.05.011 · Cited by 750
Adherence to Therapies in Patients with Type 2 Diabetes
García-Pérez, L.-E., Álvarez, M., Dilla, T., Gil-Guillén, V., & Orozco-Beltrán, D. (2013) · Diabetes Therapy · doi:10.1007/s13300-013-0034-y · Cited by 726
Huynh, K., Bernardo, B. C., McMullen, J. R., & Ritchie, R. H. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.01.003 · Cited by 553
Singh, S., Chang, H.-Y., Richards, T. M., Weiner, J. P., Clark, J. M., & Segal, J. B. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.2720 · Cited by 467
Reed, J., Bain, S., & Kanamarlapudi, V. (2021) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s319895 · Cited by 441
Recommendations for Management of Diabetes During Ramadan
Al-Arouj, M., Assaad-Khalil, S., Buse, J., Fahdil, I., Fahmy, M., Hafez, S., Hassanein, M., Ibrahim, M. A., Kendall, D., Kishawi, S., et al. (2010) · Diabetes Care · doi:10.2337/dc10-0896 · Cited by 411
Self-citationAthauda, D., & Foltynie, T. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.01.013 · Cited by 383
A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond
Prasad-Reddy, L., & Isaacs, D. (2015) · Drugs in Context · doi:10.7573/dic.212283 · Cited by 365
Insulin resistance and Parkinson’s disease: A new target for disease modification?
Athauda, D., & Foltynie, T. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.10.001 · Cited by 328
Pharmaceutical Drugs and Natural Therapeutic Products for the Treatment of Type 2 Diabetes Mellitus
Blahova, J., Martiniakova, M., Babikova, M., Kovacova, V., Mondockova, V., & Omelka, R. (2021) · Pharmaceuticals · doi:10.3390/ph14080806 · Cited by 302
Hypoglycemia: The neglected complication
Kalra, S., Mukherjee, J. J., Venkataraman, S., Bantwal, G., Shaikh, S., Saboo, B., Das, A. K., & Ramachandran, A. (2013) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.117219 · Cited by 255
Tumminia, A., Vinciguerra, F., Parisi, M., & Frittitta, L. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113306 · Cited by 249
Critical evaluation of the role of acarbose in the treatment of diabetes: patient considerations
Rosak, C., & Mertes (2012) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s28340 · Cited by 216
Manandhar, B., & Ahn, J.-M. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm500810s · Cited by 198
Alves, C., Batel-Marques, F., & Macedo, A. F. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.09.008 · Cited by 186
Drucker, D. J., Dritselis, A., & Kirkpatrick, P. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3148 · Cited by 181
Self-citationGallwitz, B., Guzman, J., Dotta, F., Guerci, B., Simó, R., Basson, B. R., Festa, A., Kiljański, J., Sapin, H., Trautmann, M., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60479-6 · Cited by 159
Ratner, R. E., Han, J., Nicewarner, D., Yushmanova, I., Hoogwerf, B. J., & Shen, L. Z. (2011) · Cardiovascular Diabetology · doi:10.1186/1475-2840-10-22 · Cited by 159
The Safety of Incretin-Based Therapies—Review of the Scientific Evidence
Drucker, D. J., Sherman, S. I., Bergenstal, R. M., & Buse, J. B. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0599 · Cited by 150
Self-citationBalena, R., Hensley, I. E., Miller, S., & Barnett, A. H. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12025 · Cited by 161
Targeting the glucagon receptor family for diabetes and obesity therapy
Cho, Y. M., Merchant, C. E., & Kieffer, T. J. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.05.009 · Cited by 156
Duarte, A. I., Candeias, E., Correia, S. C., Santos, R. X., Carvalho, C., Cardoso, S., Plácido, A. I., Santos, M. S., Oliveira, C. R., & Moreira, P. I. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.01.008 · Cited by 162
Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus
Koliaki, C., & Doupis, J. (2011) · Diabetes Therapy · doi:10.1007/s13300-011-0002-3 · Cited by 140
Metal-based anti-diabetic drugs: advances and challenges
Levina, A., & Lay, P. A. (2011) · Dalton Transactions · doi:10.1039/c1dt10380f · Cited by 148
Inflammation meets metabolic disease: Gut feeling mediated by GLP-1
Zietek, T., & Rath, E. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00154 · Cited by 131
Koehler, J. A., Kain, T., & Drucker, D. J. (2011) · Endocrinology · doi:10.1210/en.2011-1201 · Cited by 136
Self-citationThe Human GLP-1 Analog Liraglutide and the Pancreas
Nyborg, N. C. B., Mølck, A.-M., Madsen, L. W., & Bjerre Knudsen, L. (2012) · Diabetes · doi:10.2337/db11-0936 · Cited by 125
Sitagliptin Use in Patients With Diabetes and Heart Failure
Weir, D. L., McAlister, F. A., Senthilselvan, A., Minhas‐Sandhu, J. K., & Eurich, D. T. (2014) · JACC Heart Failure · doi:10.1016/j.jchf.2014.04.005 · Cited by 122
The A1C and ABCD of glycaemia management in type 2 diabetes: a physician's personalized approach
Pozzilli, P., Leslie, R. D., Chan, J. C. N., Fronzo, R. D., Monnier, L., Raz, I., & Prato, S. D. (2010) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1092 · Cited by 115
GLP‐1 based therapies: differential effects on fasting and postprandial glucose
Fineman, M., Cirincione, B., Maggs, D., & Diamant, M. (2012) · Diabetes, obesity and metabolism · doi:10.1111/j.1463-1326.2012.01560.x · Cited by 123
Samad, M. B., Mohsin, M. N. A. B., Razu, B. A., Hossain, M. T., Mahzabeen, S., Unnoor, N., Muna, I. A., Akhter, F., Kabir, A. U., & Hannan, J. M. A. (2017) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-017-1903-0 · Cited by 109
Monami, M., Dicembrini, I., Nardini, C., Fiordelli, I., & Mannucci, E. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2014.01.010 · Cited by 106
“[14] Drucker DJ, Sherman SI, Gorelick FS, Bergenstal RM, Sherwin RS, Buse JB.”
GLP-1 receptor agonists: A clinical perspective on cardiovascular effects
Mundil, D., Cameron-Vendrig, A., & Husain, M. (2012) · Diabetes and Vascular Disease Research · doi:10.1177/1479164112441526 · Cited by 104
He, J., Chen, L.-X., & Li, H. (2019) · Fitoterapia · doi:10.1016/j.fitote.2019.02.033 · Cited by 108
Optical Control of Insulin Secretion Using an Incretin Switch
Broichhagen, J., Podewin, T., Meyer‐Berg, H., von Ohlen, Y., Johnston, N. R., Jones, B. J., Bloom, S. R., Rutter, G. A., Hoffmann‐Röder, A., Hodson, D. J., et al. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201506384 · Cited by 111
Monami, M., Dicembrini, I., & Mannucci, E. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12176 · Cited by 112
Salvatore, T., Galiero, R., Caturano, A., Vetrano, E., Loffredo, G., Rinaldi, L., Catalini, C., Gjeloshi, K., Albanese, G., Di Martino, A., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10092274 · Cited by 98
“Therefore, GLP-1-based therapies including structural analogues of human endogenous GLP-1 (albiglutide, dulaglutide, liraglutide, and semaglutide) and exendin-based agents (efpeglenatide, exenatide, and lixisenatide), have emerged as major anti-hyperglycemic therapeutic options [177,178].”
BackgroundProtective effects of the GLP-1 mimetic exendin-4 in Parkinson's disease
Athauda, D. S., & Foltynie, T. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.09.023 · Cited by 99
Eurich, D. T., Simpson, S. H., Senthilselvan, A., Asche, C. V., Sandhu-Minhas, J. K., & McAlister, F. A. (2013) · BMJ · doi:10.1136/bmj.f2267 · Cited by 99
Clarifying the Role of Incretin-Based Therapies in the Treatment of Type 2 Diabetes Mellitus
Campbell, R. K. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.04.015 · Cited by 100
Zaccardi, F., Htike, Z. Z., Webb, D. R., Khunti, K., & Davies, M. J. (2016) · Annals of Internal Medicine · doi:10.7326/m15-1432 · Cited by 91
Gupta, P., Bala, M., Gupta, S. K., Dua, A., Dabur, R., Injeti, E. R., & Mittal, A. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.09.029 · Cited by 101
Giorda, C. B., Nada, E., & Tartaglino, B. (2014) · Endocrine · doi:10.1007/s12020-014-0179-0 · Cited by 89
Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy – focus on alogliptin
Giugliano, D., Sportiello, L., Capuano, A., Maiorino, M., Rossi, F., & Esposito, K. (2013) · Drug Design, Development and Therapy · doi:10.2147/dddt.s37647 · Cited by 86
de‐Madaria, E., Abad-González, Á. L., Aparicio, J. R., Aparisi, L., Boadas, J., Boix, E., de-las-Heras, G., Domínguez‐Muñoz, J. E., Farré, A., Fernández‐Cruz, L., et al. (2013) · Pancreatology · doi:10.1016/j.pan.2012.11.310 · Cited by 95
Lind, M., JENDLE, J. H., Torffvit, O., & Lager, I. (2011) · Primary care diabetes · doi:10.1016/j.pcd.2011.09.002 · Cited by 80
Pathogenesis and management of postprandial hyperglycemia: role of incretin-based therapies
Gerich, J. E. (2013) · International Journal of General Medicine · doi:10.2147/ijgm.s51665 · Cited by 95
Bailey, T. S. (2013) · The American Journal of Medicine · doi:10.1016/j.amjmed.2013.06.009 · Cited by 84
Microbial regulation of the L cell transcriptome
Arora, T., Akrami, R., Pais, R., Bergqvist, L., Johansson, B. R., Schwartz, T. W., Reimann, F., Gribble, F. M., & Bäckhed, F. (2018) · Scientific Reports · doi:10.1038/s41598-017-18079-2 · Cited by 74
Diabetes and Alzheimer’s Disease: Might Mitochondrial Dysfunction Help Deciphering the Common Path?
Potenza, M. A., Sgarra, L., Desantis, V., Nacci, C., & Montagnani, M. (2021) · Antioxidants · doi:10.3390/antiox10081257 · Cited by 87
Lee, H., An, J., Kim, J., Choi, D., Song, Y., Lee, C., Kong, H., Kim, S. B., & Kim, K. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.858192 · Cited by 82
GLP-1–Based Therapy for Diabetes: What You Do Not Know Can Hurt You
Butler, P. C., Dry, S., & Elashoff, R. M. (2010) · Diabetes Care · doi:10.2337/dc09-1902 · Cited by 77
Koren, S., Shemesh-Bar, L., Tirosh, A., Peleg, R. K., Berman, S., Hamad, R. A., Vinker, S., Golik, A., & Efrati, S. (2012) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2011.0296 · Cited by 76
Type 2 diabetes mellitus—current therapies and the emergence of surgical options
Lebovitz, H. E. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.10 · Cited by 73
Kim, K., Yang, H. J., Lee, I., Kim, K., Park, J., Jeong, H.-S., Kim, Y., Ahn, K. S., Na, Y., & Jang, H.-J. (2015) · Scientific Reports · doi:10.1038/srep18325 · Cited by 72
Ramadan and diabetes: As-Saum (The fasting)
Jaleel, M., Raza, S., Fathima, F., & Jaleel, B. N. (2011) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.85578 · Cited by 67
Abrahami, D., Douros, A., Yin, H., Yu, O. H., Faillie, J., Montastruc, F., Platt, R. W., Bouganim, N., & Azoulay, L. (2018) · BMJ · doi:10.1136/bmj.k4880 · Cited by 71
Recent Developments in Therapeutic Peptides for the Glucagon-like Peptide 1 and 2 Receptors
Suzuki, R., Brown, G. A., Christopher, J. A., Scully, C. C. G., & Congreve, M. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00835 · Cited by 64
Al‐Rashed, F., Sindhu, S. T. A. K., Arefanian, H., Madhoun, A. S. A., Kochumon, S., Thomas, R., Al-Kandari, S., Alghaith, A., JACOB, T. K., Al‐Mulla, F., et al. (2020) · Cells · doi:10.3390/cells9081892 · Cited by 67
GPR119 Agonists for the Potential Treatment of Type 2 Diabetes and Related Metabolic Disorders
Shah, U., & Kowalski, T. J. (2010) · Vitamins and hormones · doi:10.1016/b978-0-12-381517-0.00016-3 · Cited by 74
Molecular Mechanisms Underlying the Cardiovascular Benefits of SGLT2i and GLP-1RA
Khat, D. Z., & Husain, M. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1011-7 · Cited by 66
Type 2 Diabetes (T2DM) and Parkinson’s Disease (PD): a Mechanistic Approach
Sabari, S. S., Balasubramani, K., Iyer, M., Babu, H. W. S., Venkatesan, D., Gopalakrishnan, A. V., Narayanaswamy, A., Kumar, N. S., & Vellingiri, B. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03359-y · Cited by 68
Jeon, J. Y., Kim, D. J., Ko, S., Kwon, H., Lim, S. K., Choi, S. H., Kim, C. S., An, J. H., Kim, N. H., Won, J. C., et al. (2014) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2014.38.3.197 · Cited by 61
Importance of Postprandial Glucose in Relation to A1C and Cardiovascular Disease
Hershon, K. S., Hirsch, B. R., & Odugbesan, O. (2019) · Clinical Diabetes · doi:10.2337/cd18-0040 · Cited by 67
Bioactive peptides identified from enzymatic hydrolysates of sturgeon skin
Gui, M., Gao, L., Rao, L., Li, P., Zhang, Y., Han, J., & Li, J. (2021) · Journal of the Science of Food and Agriculture · doi:10.1002/jsfa.11532 · Cited by 58
Shao, N., Yu, X., Ma, X., Lin, W., Hao, M., & Kuang, H. (2018) · Gastroenterology Research and Practice · doi:10.1155/2018/1864307 · Cited by 60
Pendergrass, M., Fenton, C., Haffner, S. M., & Chen, W. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01567.x · Cited by 53
Gu, N., Park, M. K., Kim, T., Bahng, M. Y., Cho, S., Yoon, S. H., Cho, J., Jang, I., Yu, K., & Lim, K. S. (2014) · Drug Design Development and Therapy · doi:10.2147/dddt.s65678 · Cited by 57
Incretin-Based Therapies and Diabetic Retinopathy: Real-World Evidence in Older U.S. Adults
Wang, T., Hong, J., Gower, E. W., Pate, V., Garg, S., Buse, J. B., & Stürmer, T. (2018) · Diabetes Care · doi:10.2337/dc17-2285 · Cited by 55
Self-citationRoy, S., Ghosh, A., Majie, A., Karmakar, V., Das, S., Dinda, S. C., Bose, A., & Gorain, B. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.155638 · Cited by 64
Isolation and in silico evaluation of antidiabetic molecules of Cynodon dactylon (L.)
Annapurna, H. V., Apoorva, B., Natesan, R., Purushothaman, A. K., Brindha, P., Swaminathan, S., Vijayalakshmi, M., & Arumugam, N. (2012) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2012.10.009 · Cited by 53
An Updated Review on Cancer Risk Associated with Incretin Mimetics and Enhancers
Tseng, C.-H., Lee, K.-Y., & Tseng, F.-H. (2015) · Journal of Environmental Science and Health, Part C · doi:10.1080/10590501.2015.1003496 · Cited by 49
“These agents, especially the oral form of DPP-4 inhibitors, are widely used by clinicians in the past decade for their durable metabolic advantages (effective glucose-lowering, low risk of hypoglycemia, and weight neutral or even weight loss with GLP-1R agonists) and the beneficial or neutral cardiovascular effects [5…”
BackgroundBrunell, S. C., Toth, P. P., Ramírez, G., Cobble, Chilton, & Chiquette (2012) · Vascular Health and Risk Management · doi:10.2147/vhrm.s37969 · Cited by 49
Liu, Y., Wei, R., & Hong, T. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i27.9090 · Cited by 55
Anti-diabetic effects of natural products an overview of therapeutic strategies
Park, J., & Jang, H.-J. (2017) · Molecular & Cellular Toxicology · doi:10.1007/s13273-017-0001-1 · Cited by 53
Hou, Y., Ernst, S. A., Heidenreich, K., & Williams, J. A. (2015) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00293.2015 · Cited by 53
Tatosian, D. A., Guo, Y. Q., Schaeffer, A. K., Gaibu, N., Popa, S., Stoch, A., Langdon, R. B., & Kauh, E. A. (2013) · Diabetes Therapy · doi:10.1007/s13300-013-0045-8 · Cited by 47
Mechanism of the antidiabetic action of Nigella sativa and Thymoquinone: a review
Shaukat, A., Zaidi, A., Anwar, H., & Kizilbash, N. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2023.1126272 · Cited by 67
Use of incretin agents and risk of pancreatic cancer: a population‐based cohort study
Knapen, L. M., van Dalem, J., Keulemans, Y. C., van Erp, N. P., Bazelier, M. T., De Bruin, M. L., Leufkens, H. G. M., Croes, S., Neef, C., de Vries, F., et al. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12605 · Cited by 43
(2020) · Progress in Brain Research · doi:10.1016/bs.pbr.2019.10.008 · Cited by 44
Girard, R., Tremblay, S., Noll, C., St‐Jean, S., Jones, C. M., Gélinas, Y., Maloum-Rami, F., Perreault, N., Laplante, M., Carpentier, A. C., et al. (2022) · Nature Communications · doi:10.1038/s41467-021-27934-w · Cited by 47
Use of incretin agents and risk of acute and chronic pancreatitis: A population‐based cohort study
Knapen, L. M., de Jong, R. G. P. J., Driessen, J. H. M., Keulemans, Y. C. A., van Erp, N. P., Bruin, M. L. D., Leufkens, H. G. M., Croes, S., & de Vries, F. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12833 · Cited by 46
Functional importance of GLP-1 receptor species and expression levels in cell lines
Knudsen, L. B., Hastrup, S., Underwood, C. R., Wulff, B. S., & Fleckner, J. (2012) · Regulatory Peptides · doi:10.1016/j.regpep.2011.12.006 · Cited by 42
Vildagliptin topical ointment: an effective treatment for imiquimod-induced psoriasis in mice
Ali, B. F., Abu-Raghif, A. R., Ridha‐Salman, H., & Al-Athari, A. J. H. (2025) · Journal of Molecular Histology · doi:10.1007/s10735-025-10416-4 · Cited by 40
Acute tubulointerstitial nephritis following treatment with exenatide
Nandakoban, H., Furlong, T. J., & Flack, J. R. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03738.x · Cited by 40
Diabetes treatments and cancer risk: the importance of considering aspects of drug exposure
Walker, J. J., Johnson, J. A., & Wild, S. H. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70028-7 · Cited by 38
Mondragon, A., Davidsson, D., Kyriakoudi, S., Bertling, A., Gomes-Faria, R., Cohen, P., Rothery, S., Chabosseau, P., Rutter, G. A., & da Silva Xavier, G. (2014) · PLoS ONE · doi:10.1371/journal.pone.0104873 · Cited by 37
Huang, J.-H., Chen, Y.-C., Lee, T.-I., Kao, Y.-H., Chazo, T.-F., Chen, S.-A., & Chen, Y.-J. (2016) · Peptides · doi:10.1016/j.peptides.2016.02.007 · Cited by 36
Griffin, J. W. D., Liu, Y., Bradshaw, P. C., & Wang, K. (2018) · Journal of Molecular Neuroscience · doi:10.1007/s12031-018-1035-0 · Cited by 38
Non-alcoholic Fatty Liver Disease: A Review of Anti-diabetic Pharmacologic Therapies
Snyder, H. S., Sakaan, S. A., March, K. L., Siddique, O., Cholankeril, R. T., Cummings, C. D., Gadiparthi, C., Satapathy, S. K., Ahmed, A., & Cholankeril, G. T. (2018) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2017.00050 · Cited by 42
SGLT inhibitors as antidiabetic agents: a comprehensive review
Kshirsagar, R. P., Kulkarni, A. A., Chouthe, R. S., Pathan, S. K., Une, H. D., Reddy, G. B., Diwan, P. V., Ansari, S. A., & Sangshetti, J. N. (2020) · RSC Advances · doi:10.1039/c9ra08706k · Cited by 45
Myasoedova, V. A., Bozzi, M., Valerio, V., Moschetta, D., Massaiu, I., Rusconi, V., Di Napoli, D., Ciccarelli, M., Parisi, V., Agostoni, P., et al. (2023) · Antioxidants · doi:10.3390/antiox13010016 · Cited by 35
Diabetes and Ramadan: How to Achieve a Safer Fast for Muslims with Diabetes
Hassanein, M. M. (2010) · The British Journal of Diabetes · doi:10.1177/1474651410380150 · Cited by 34
Dalle, S., Ravier, M. A., & Bertrand, G. (2010) · Cellular Signalling · doi:10.1016/j.cellsig.2010.09.014 · Cited by 39
The effects of liraglutide in mice with diet-induced obesity studied by metabolomics
Bugáňová, M., Pelantová, H., Holubová, M., Šedivá, B., Maletínská, L., Železná, B., Kuneš, J., Kačer, P., Kuzma, M., & Haluzík, M. (2017) · Journal of Endocrinology · doi:10.1530/joe-16-0478 · Cited by 36
Fighting Diabetes Mellitus: Pharmacological and Non-pharmacological Approaches
Wang, X., Kang, J., Liu, Q., Tong, T., & Quan, H. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200728144200 · Cited by 45
Jonik, S., Marchel, M., Grabowski, M., Opolski, G., & Mazurek, T. (2022) · Biology · doi:10.3390/biology11020288 · Cited by 33
Type 2 Diabetes Mellitus and Glucagon Like Peptide-1 Receptor Signalling
Thompson, K. A. (2013) · Clinical and Experimental Pharmacology · doi:10.4172/2161-1459.1000138 · Cited by 49
Kahleová, H., Mari, A., Nofrate, V., Matoulek, M., Kazdová, L., Hill, M., & Pelikánová, T. (2012) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2012.05.003 · Cited by 38
Metadata
- Authors
- Drucker, D. J., Sherman, S. I., Gorelick, F. S., Bergenstal, R. M., Sherwin, R. S., & Buse, J. B.
- Affiliations
- University of Toronto (CA)
- The University of Texas MD Anderson Cancer Center (US)
- Yale University (US)
- Park Nicollet Health Services (US)
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Drucker, Daniel J.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2010-02-01
- Volume
- 33
- Issue
- 2
- Pages
- 428-433
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC2809297
- OpenAlex
- W2134760433
- Cited by
- 316
- References
- 40
- Citations by year
- 2026: 10 · 2025: 10 · 2024: 10 · 2023: 10 · 2022: 13 · 2021: 15 · 2020: 11 · 2019: 17 · 2018: 17 · 2017: 15 · 2016: 20 · 2015: 24 · 2014: 28 · 2013: 33 · 2012: 31
- FWCI
- 28.47
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- V Foundation for Cancer Research
- Park Nicollet Foundation
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Celgene
- F. Hoffmann-La Roche
- Exelixis
- Insulet Corporation
- MannKind Corporation
- ResMed
- Eisai
- Novo Nordisk
- Plexxikon
- National Institutes of Health
- National Cancer Institute
- National Institute of Diabetes and Digestive and Kidney Diseases (T32DK007017)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- type 2 diabetes, incretin-based therapy, GLP-1 receptor agonists, DPP-4 inhibitors, glycemic control, insulin resistance, insulin secretion, diabetes complications, drug safety, obesity
- MeSH terms
- Exenatide, Diabetes Mellitus, Type 2, Drug Administration Schedule, Humans, Hypoglycemic Agents, Peptides, Venoms, Incidence, Prevalence, Treatment Outcome, Risk Assessment, Glucagon-Like Peptide 1, Incretins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.